China proposes changes to foreign company patent rules report: related news

China proposes changes to foreign company patent rules - report

BEIJING (XFN-ASIA) - Foreign companies making discoveries in China will have to file for patents here or risk losing legal protection for their intellectual property, the Financial Times reported, citing proposed amendments to the patent law. The amendments, which could become law this year, come at a time when foreign companies including Microsoft are setting up research centers in China as they look to expand sales in the market, the newspaper noted. If foreign companies fail to register Chinese discoveries first in China, rivals will be able to challenge the validity of any subsequent domestic patent and potentially block sales in the local market, the newspaper said. Another proposal involves the adoption of an 'absolute novelty' standard that will make it hard to get a Chinese patent for inventions that are already in use overseas, i

China proposes changes to foreign company patent rules - report

BEIJING (XFN-ASIA) - Foreign companies making discoveries in China will have to file for patents here or risk losing legal protection for their intellectual property, the Financial Times reported, citing proposed amendments to the patent law.

Foreigners may face tighter Chinese patent laws

Foreign companies that make discoveries in China would have to file for a patent in China before anywhere else or risk losing protection of their intellectual property, according to proposed changes to the country's patent law. Another proposal calls for the introduction of an "absolute novelty" standard, which would make it more difficult to obtain a patent in China for inventions already in use overseas. Experts said the changes, which could come into effect this year, would make it easier to challenge rogue Chinese patents, the Financial Times reported. However, the experts also warned that conditions are likely to become more challenging for foreign firms conducting research in China. At present, most of these firms choose to file for patent protection in their home countries, where patent legislation is more mature and robust than in

China In-Focus: China Medicine Retains Australian Patent

July 18, 2008 (FinancialWire) China Medicine Corp. (OTCBB: CHME) (Current Market Cap. US$28.96 Mil.) has obtained a patent from Australia Patent Office for recombinant Aflatoxin Detoxifizyme. The patent is valid through January 13, 2025. According to China Medicine, rADTZ is a product that has the potential to detoxify aflatoxin, a potential cancer causing agent, in food and feed. It is a compound that is a derivation of aflatoxin-detoxifizyme, an extracellular enzyme. Developed by Guangzhou Co-Win Bioengineering Co., Ltd., a subsidiary of China Medicine, rADTZ can be used as an additive to remove aflatoxins from animal feed as well as other food products. The company intends to develop rADTZ for this and other applications. The company is currently testing rADTZ on animal feed and is scheduled to begin working with the Chinese Department

China proposes changes to foreign company patent rules - report

The summer box office often sizzles as the calendar turns to July. What movies have opened best on the Independence Day holiday weekend?

International Companies Require China-Specific Patent Strategies

Shanghai, China – May 22, 2008: China, one of the world’s largest and most promising markets, has seen a 20 percent annual increase in patent application filings over the last fifteen years. In 2007, the State Intellectual Property Office (SIPO) of China received 694,153 patent applications, an increase of 21.1 percent over the previous year. These applications included filings for all three types of patents granted in China: Invention patents (valid for 20 years from the date of filing), Utility Models (valid for 10 years), and Design patents (also valid for 10 years). With regard to invention patents (20 year patents), China is currently third in the world behind the United States and Japan. In its latest study, Evalueserve, a global research and analytics firm, forecasts that if patent filings in China continue to grow at the current r

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Personal Group Holdings Plc - Financial Services - Insurance - SWOT Report

Personal Group Holdings Plc SWOT Report is a comprehensive report of the company including both quantitative and qualitative research. The report examines the company’s business structure and operations, history and products. The report provides strategic insight on the company in the form of a SWOT analysis. This studies the major internal factors which will affect the company’s performance e.g. size, strength, cost, revenues and strategy as well as external factors e.g. competitive positioning and industry trends. There is a forward-looking discussion of the opportunities the company can exploit and the threats facing it.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

MedMira Awarded China Patent

MedMira Inc. announced that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No. 10/163,675) and the European Union (European Patent No. EP1417489).

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

China In-Focus: Liberty Alliance Completes Reverse Stock Split, Changes Name

July 18, 2008 (FinancialWire) The board of directors and stockholders of Liberty Alliance Inc. (OTCBB: SIHI) (Current Market Cap. US$63.00 Mil.) have approved a 1-for-3.5 reverse stock split of the company's outstanding common stock and a name change to SinoHub Inc. The company s symbols also changed; SinoHub previously traded with the symbol LBTI. As a result of the reverse stock split, every 3.5 shares of the company's common stock will be combined into one share of the company's common stock. The reverse stock split affects all shares of common stock and stock options of the company outstanding as of immediately prior to the effective time of the reverse stock split. The number of shares of the company's common stock currently outstanding is approximately 70 million prior to the reverse stock split and will be reduced to approximately

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,” said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

E-tailing: Report Out on E-Commerce in China

Paul Denlinger over at China Vortex points us to a new report from the Research Institute Data Center of China Internet, which claims that online spending in China passed $37.5 billion in the first six months of the year, representing a 58.2% jump over the same period in 2007. The report goes on to predict that overall spending online in China will surpass $86 billion for all of 2008.

MedMira Awarded China Patent to Complete IP Triple Crown

HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

MedMira Awarded China Patent to Complete IP Triple Crown

HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

MedMira Awarded China Patent to Complete IP Triple Crown

Rapid Flow-Through Technology Patents in Three Major Global Markets HALIFAX (CNW) - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

MIT sues Affymetrix for patent infringement

Affymetrix, the Santa Clara maker of tools used to study DNA and diagnose diseases, was sued for patent infringement by the Massachusetts Institute of Technology over the company's GeneChip system used to analyze genes. Affymetrix has knowingly infringed the patent, MIT and a company started by an MIT professor said in a federal court complaint filed Tuesday in Boston. Affymetrix filed an application with the U.S. Patent and Trademark Office in September 2004, six months after a similar patent was approved for MIT, the university said in its complaint. The patent regulators ruled in May 2007 that the MIT group was the first inventor, according to the complaint. The GeneChip technology is used to develop new therapeutic drugs and to investigate the cause of cancer, AIDS and other diseases, Affymetrix has said.

SOA & Web Services - Business Rules Caf

One of the hardest things for most IT departments is change. Not only do they have to cope with the technology change that is inherent in their business, they have to cope with all sorts of other change - regulatory changes, business changes, competitive changes, requirement changes, process changes, policy changes. All this change creates a maintenance nightmare so that in many IT shops most of the time is spent not in building cool new applications but editing and "fixing" code in old systems. Business rules, one of the fastest-growing markets in application development technology, offers a way to stop worrying about change and learn to love it.

Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants

WASHINGTON, July 29 /PRNewswire-USNewswire/ -- A coalition of consumer advocacy and public interest groups today filed legal papers supporting new U.S. Patent Office (USPTO) rules that would curtail abusive behavior by patent applicants and improve patent quality. The tactics are used frequently by drug companies to get patents they don't deserve.

Search took 0.82 seconds.